Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study developed a biodegradable nanofibrous biofilm that attracts skin-related cells and accelerates blood vessel formation, potentially improving skin wound healing.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This case report describes successful treatment of a 21-year-old patient with lichen planopilaris using keratolytic lotions, a combination of corticosteroids, salicylic acid, and tacrolimus cream, which stopped disease progression.

Lactium, a milk protein, can help reduce symptoms of skin disorders linked to stress and anxiety without side effects.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

In this study, the combination of Poly-D,L-Lactic Acid and Platelet-Rich Plasma was reported to be effective for improving wrinkle severity and skin brightness in a 45-year-old woman.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

Lye relaxers don't significantly change hair cortisol levels.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

A 5-year-old girl with a rare skin disorder was effectively treated with skin creams instead of oral medication.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This study found that alkylation of kerateine cysteine residues created a cell-compatible method for controlling hydrogel erosion rates and therapeutic agent release in keratin-based systems.

This study reports that 0.025% tretinoin lotion seemed effective for idiopathic hair casts in two young girls and suggests an infrainfundibular origin for the lesions.

This in-vitro study reported that a luliconazole-based formulation improved hair cuticle integrity and was more effective than ketoconazole in repairing damaged hair after 5 and 10 washes, with sensory analysis supporting these results. Further human studies are needed to confirm its clinical effects.

This paper reviews treatments for lichen planopilaris, including low-level laser therapy, but reports no new clinical results and highlights the need for further research.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This study suggests that combining tranexamic acid with low-dose oral retinoids may offer moderate to good improvements for lichen plan pigmentosus, although larger trials are needed for confirmation.

This review explores the immunological aspects of epidermal differentiation in loricrin knockout mice, offering insights into keratinization and potential intrinsic factors affecting immune function, but provides no new clinical findings.

This study found that RALF peptides, through liquid-liquid phase separation, form condensates with pectin and other proteins, playing a pivotal role in plant development and stress response regulation.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.